Taysha gene therapies to release full-year 2023 financial results, provide corporate and clinical updates and host conference call on march 19

Dallas, march 14, 2024 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha) (taysha or the company), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (cns), today announced that it will report its financial results for the full-year ended december 31, 2023, provide corporate and clinical updates and host a corporate update conference call on tuesday, march 19, 2024, at 4:30 pm eastern time.
TSHA Ratings Summary
TSHA Quant Ranking